TV News LIES

Tuesday, May 03rd

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Court: NFL Must Reveal Concussion Documents

Concussion documents must be revealedNational Football League executives may for the first time have to testify about what they knew...

Mumps cases hit 40 as Harvard begs students: Stop infecting each other

Mumps cases hit 40 in HarwardA mumps outbreak that began two months ago at Harvard University is getting worse.  More than...

Cost for new oral cancer drugs skyrocketed in last decade

Cost of oral cancer drug sky rocketedA new drug for cancer introduced in 2014 costs about six times the price of a...

30 years later, Chernobyl disaster could trigger more cancer, deaths

Chernobyl 30 years laterThree decades after the Chernobyl nuclear power plant exploded and sent a plume of radiation as...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!